Filing Flows › Comparisons › PRPH vs CPHI
ProPhase Labs vs China Pharma Holdings: PRPH and CPHI compared
ProPhase Labs is the larger company: $1.0M of revenue in its latest quarter (Q2 2026) against $948K for China Pharma Holdings (Q2 2026). China Pharma Holdings is growing faster (-8% against -19% a year earlier). China Pharma Holdings is more profitable, with an operating margin of -151.0% against -261.6%.
Where the money goes: PRPH and CPHI
ProPhase Labs (PRPH) · Q2 2026
ProPhase Labs, Q2 2026: revenue $1.0M (-19% year over year), operating margin -261.6%, net loss $3.1M, operating cash flow −$78K. The chart follows the revenue to costs, profit and cash.
China Pharma Holdings (CPHI) · Q2 2026
China Pharma Holdings, Q2 2026: revenue $948K (-8% year over year), operating margin -151.0%, net loss $1.5M, operating cash flow −$33K. The chart follows the revenue to costs, profit and cash.
| ProPhase Labs (PRPH) | China Pharma Holdings (CPHI) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2026 |
| Revenue | $1.0M | $948K |
| Revenue growth, Y/Y | -19% | -8% |
| Operating margin | -261.6% | -151.0% |
| Net earnings | −$3.1M | −$1.5M |
| Net margin | -301.8% | -153.8% |
| Operating cash flow | −$78K | −$33K |
Questions
Which is bigger, ProPhase Labs or China Pharma Holdings?
ProPhase Labs is the larger company: $1.0M of revenue in its latest quarter (Q2 2026) against $948K for China Pharma Holdings (Q2 2026).
Is ProPhase Labs or China Pharma Holdings growing faster?
China Pharma Holdings is growing faster (-8% against -19% a year earlier).
Which is more profitable, ProPhase Labs or China Pharma Holdings?
China Pharma Holdings is more profitable, with an operating margin of -151.0% against -261.6%.
More: ProPhase Labs earnings · how ProPhase Labs makes money · China Pharma Holdings earnings · how China Pharma Holdings makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 19, 2026; 10-Q filed Aug 14, 2026). Fiscal quarters can end on different dates. Not investment advice.